<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(mark one)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______________ TO _____________
COMMISSION FILE NUMBER 0-20096
GLIATECH INC.
(Exact name of registrant as specified in its charter)
DELAWARE 34-1587242
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
23420 COMMERCE PARK ROAD
CLEVELAND, OHIO 44122
(Address of principal executive offices) (Zip Code)
(216) 831-3200
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO
--- ---
The number of shares outstanding of the registrant's Common Stock, $0.01 par
value per share, as of May 10, 1999 was 9,672,942 shares.
<PAGE> 2
GLIATECH INC. AND SUBSIDIARIES
INDEX
PART I. FINANCIAL INFORMATION PAGE
----
Item 1 Financial Statements:
Consolidated Balance Sheets - 1
December 31, 1998 and March 31, 1999 (unaudited)
Consolidated Statements of Operations -
for the three months ended March 31, 1999 and 1998 (unaudited) 2
Consolidated Statements of Cash Flows -
for the three months ended March 31, 1999 and 1998 (unaudited) 3
Notes to Consolidated Financial Statements 4
Item 2 Management's Discussion and Analysis of Financial Condition 5-11
and Results of Operations
Item 3 Quantitative and Qualitative Disclosures About Market Risk 12
PART II. OTHER INFORMATION
Item 2 Changes in Securities and Use of Proceeds 13
Item 6 Exhibits and Reports on Form 8-K 14
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
GLIATECH INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1999 1998
------------ ------------
(unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 3,553,982 $ 4,731,814
Short-term investments 22,641,382 21,667,064
Accounts receivable 3,503,484 2,995,548
Government grants receivable 380,365 401,160
Inventories 1,298,075 776,057
Prepaid expenses and other 501,972 1,016,098
------------ ------------
Total current assets 31,879,260 31,587,741
Property and equipment, net 2,067,307 1,556,815
Other assets, net 702,659 817,630
------------ ------------
TOTAL ASSETS $ 34,649,226 $ 33,962,186
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable 515,908 875,462
Accrued expenses 2,465,310 2,083,273
Accrued research contracts 1,045,761 1,418,653
Accrued compensation 291,426 790,041
Accrued clinical trial costs 2,103,592 1,127,991
Deferred research contract revenue 171,398 514,194
------------ ------------
Total current liabilities 6,593,395 6,809,614
Stockholders' equity:
Common stock 94,695 94,109
Additional paid-in capital 73,259,384 72,830,961
Accumulated deficit (45,298,248) (45,772,498)
------------ ------------
Total stockholders' equity 28,055,831 27,152,572
------------ ------------
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY $ 34,649,226 $ 33,962,186
============ ============
</TABLE>
See notes to consolidated financial statements
1
<PAGE> 4
GLIATECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31
------------------------------
1999 1998
----------- -----------
<S> <C> <C>
REVENUES
Product sales $ 7,756,270 $ 511,500
Research contracts and licensing fees 342,796 738,500
Government grants 185,683 150,335
----------- -----------
Total revenues 8,284,749 1,400,335
OPERATING COSTS AND EXPENSES
Cost of products sold 1,147,130 166,834
Research and development 3,858,037 2,253,014
Selling, general and administrative 2,933,141 1,232,873
Depreciation and amortization 125,467 86,848
----------- -----------
Total operating costs and expenses 8,063,775 3,739,569
----------- -----------
Operating income (loss) 220,974 (2,339,234)
Interest income, net 253,268 146,808
----------- -----------
NET INCOME (LOSS) $ 474,242 $(2,192,426)
=========== ===========
Earnings (loss) per share
Basic $ 0.05 $ (0.29)
=========== ===========
Diluted $ 0.05 $ (0.29)
=========== ===========
Average shares outstanding
Basic 9,429,875 7,451,273
=========== ===========
Diluted 10,154,459 7,451,273
=========== ===========
</TABLE>
See notes to consolidated financial statements
2
<PAGE> 5
GLIATECH INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
-------------------------------
1999 1998
----------- -----------
<S> <C> <C>
OPERATING ACTIVITIES
Net income (loss) $ 474,242 ($2,192,426)
Adjustments to reconcile net income (loss) to net cash provided
by (used in) operating activities:
Depreciation and amortization 125,467 86,848
Patent Cost Write-off 178,122 24,999
Compensation from issuance of stock and stock options 176,600 0
Changes in operating assets and liabilities:
Accounts receivable (507,936) 54,250
Inventory (522,018) (396,408)
Government grants receivable and other assets 534,921 31,098
Accounts payable (359,555) (184,265)
Deferred contract research revenue (342,796) (738,499)
Other liabilities 486,131 (31,363)
----------- -----------
Net cash provided by (used in) operating activities 243,178 (3,345,766)
INVESTING ACTIVITIES
(Purchase) sale of investments, net (974,318) 595,399
Payment for patent rights and trademarks (71,453) (56,926)
Purchase of property and equipment (627,656) (97,068)
----------- -----------
Net cash (used in) provided by investing activities (1,673,427) 441,405
FINANCING ACTIVITIES
Proceeds from exercise of stock options 252,417 0
----------- -----------
Net cash provided by financing activities 252,417 0
----------- -----------
Decrease in cash and cash equivalents (1,177,832) (2,904,361)
Cash and cash equivalents at beginning of period 4,731,814 5,601,398
----------- -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 3,553,982 $ 2,697,037
=========== ===========
</TABLE>
3
<PAGE> 6
GLIATECH INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Note 1. Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the three month period ended March 31, 1999
are not necessarily indicative of the results that may be expected for the year
ending December 31, 1999. These financial statements should be read in
conjunction with the consolidated financial statements and footnotes thereto
included in the Annual Report on Form 10-K of Gliatech Inc. for the fiscal year
ended December 31, 1998 filed with the Securities and Exchange Commission.
Note 2. Basic and Diluted Earnings (Loss) per Common Share
Basic earnings (loss) per common share is based on the weighted average number
of common shares outstanding for the three months ended March 31, 1999 and 1998.
Diluted earnings (loss) per common share for the three months ended March 31,
1999 is based on the weighted average number of common shares outstanding plus
the dilutive effect of stock options.
Note 3. Business Segment
The Company operates in one business segment. It is engaged in the development
and commercialization of the Company's principal products, the ADCON(R) family,
which are medical devices designed to inhibit excess postsurgical scarring and
adhesion following surgery. The Company sells ADCON(R) products to independent
distributors in approximately 29 countries and directly to hospitals in the
United States. The Company does not have foreign facilities and therefore does
not measure operating profit or loss from foreign sales.
Domestic and foreign product sales are as follows:
<TABLE>
<CAPTION>
Three Months Ended
March 31,
----------------------------
1999 1998
---------- ----------
<S> <C> <C>
Domestic product sales $6,831,494 $ 0
Foreign product sales 924,776 511,500
---------- ----------
Total product sales $7,756,270 $ 511,500
========== ==========
</TABLE>
4
<PAGE> 7
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
The Company is engaged in research, development and commercialization of the
ADCON(R) family of products, which are proprietary, resorbable, carbohydrate
polymer medical devices designed to inhibit surgical scarring and adhesions.
Based on European pivotal clinical studies and other compliance efforts and
submission of data, the Company obtained regulatory clearance to affix CE
Marking on ADCON(R)-L and ADCON(R)-T/N in August 1995 and January 1996,
respectively, thereby allowing ADCON(R)-L and ADCON(R)-T/N to be marketed in the
19 European countries which recognize CE marking for lumbar disc surgery and
tendon and peripheral nerve surgeries respectively. The Company is currently
marketing ADCON(R)-L in 30 countries including the U.S. and ADCON(R)-T/N in 28
countries outside of the U.S. through independent medical device distributors,
including the major countries in the European Union pursuant to its CE Marking.
The Company also commenced sales of ADCON(R)-L in the U.S. in June 1998. In
addition, the Company signed a development and exclusive license agreement in
December 1996 with Chugai for the sale of ADCON(R)-L and ADCON(R)-T/N in Japan.
Further, the Company is also pursuing the development of small molecule drug
candidates for the treatment of several nervous system disorders, including
Attention Deficit Hyperactive Disorder ("ADHD"), sleep disorders, anxiety and
Alzheimer's disease ("AD"). In October 1994, the Company entered into a
strategic alliance with Janssen Pharmaceutica, N.V. of Belgium ("Janssen") to
collaborate on the discovery and development of therapeutic models to treat AD.
In October 1998, this alliance was restructured to provide for further research
by the Company until May 1999. The Company is currently negotiating to extend
the terms of this arrangement.
The Company receives a significant portion of its revenues from product sales
particularly of ADCON(R)-L and, to a lesser extent ADCON(R)-T/N. The Company
anticipates that a significant portion of revenue from product sales will be
derived from its Adcon(R) family of products, primarily ADCON(R)-L. In addition
to funds derived from contract research payments relating to its strategic
alliance with Janssen, the Company also receives revenue from various government
grants awarded to the Company. In June 1998, the Company received net proceeds
of approximately $18.9 million in connection with the completion of a public
offering of 1,725,000 shares of Common Stock.
5
<PAGE> 8
RESULTS OF OPERATIONS
For the three month period ended March 31, 1999 and 1998.
REVENUES
Total revenues increased to $8.3 million in the first quarter of 1999 from $1.4
million in the first quarter of 1998. The increase in total revenues is
primarily the result of an increase in product sales, which increased to a
record $7.8 million in the first quarter of 1999 from $511,500 million in the
first quarter of 1998. This increase in product sales resulted primarily from
the commercialization in the U.S. of ADCON(R)-L. which was approved for
marketing by the Food and Drug Administration (the "FDA") in May 1998. The
Company commenced sales of ADCON(R)-L in the U.S. in June 1998.
This increase in revenues was partially offset by a decrease in the Company's
research contract revenues of 53.6% to $342,796 in the first quarter of 1999
from $738,500 in the first quarter of 1998. These research contract revenues
were from the Company's research contract with Janssen, which was restructured
in October 1998 to provide for continued research by the Company and revenues
from Janssen until May 1999.
In addition, the Company's government-funded grant revenues increased 23.5% to
$185,683 in the first quarter of 1999 from $150,335 in the first quarter of
1998. This increase was a result of an increase in the number of
government-funded grants to the Company.
OPERATING COSTS AND EXPENSES
Total operating expenses increased by 115.6% to $8.1 million in the first
quarter of 1999, compared to $3.7 million in the first quarter of 1998. Cost of
products sold increased to $1.1 million in the first quarter of 1999 compared to
$166,834 in the first quarter of 1998, but decreased, as a percentage of product
sales, in the first quarter of 1999 to 14.8% from 32.67% in the first quarter of
1998. The percentage decrease in first quarter of 1999 is primarily due to: (i)
increased production volumes and (ii) the favorable impact of the unit sales
prices of ADCON(R)-L in the United States
Research and development expenses increased by 71.2 % to $3.9 million in the
first quarter of 1999 from $2.3 million in the first quarter of 1998. This
increase was primarily due to: i) an increase in development expenses for the
Company's lead compound for its Cognition Modulation program, which began human
clinical trial in the fourth quarter of 1998 and ii) increased clinical research
costs associated with the U.S. pivotal clinical trial of ADCON(R)-P, which
started in the first quarter of 1999.
6
<PAGE> 9
Selling, general and administrative expenses increased 137.9% to $2.9 million in
the first quarter of 1999 compared to $1.2 million in the first quarter of 1998.
This increase was primarily due to an increase in the sales and marketing
expenses and sales commissions resulting from the sales and marketing of
ADCON(R)-L in the U.S and a $178,122 write-off of abandoned patents.
Depreciation and amortization expense increased 44.5% to $125,467 in the first
quarter of 1999 compared to $86,848 in the first quarter of 1998. The increase
was primarily due to increased depreciation on purchasing of additional computer
and manufacturing equipment.
INTEREST INCOME
Interest income, net increased to $253,265 in the first quarter of 1999 from
$146,808 in the first quarter of 1998. This increase in the first quarter is due
to carrying higher cash, cash equivalents and short-term investment balances due
to the proceeds from the public offering in June 1998.
NET INCOME (LOSS)
Gliatech's net income increased to $474,242 in the first quarter of 1999,
compared to a net loss of $2.2 million in the first quarter of 1998. The net
income is a result of ADCON(R)-L product sales in the U.S. significantly offset
by an increase in total expenses. The basic and diluted earnings per common
share was $0.05 in the first quarter of 1999, compared to a net loss per common
share of $0.29 in the first quarter of 1998.
LIQUIDITY AND CAPITAL RESOURCES
In order to preserve principal and maintain liquidity, the Company's funds are
invested in commercial paper and other short-term investments. As of March 31,
1999 and December 31, 1998, the Company's cash and cash equivalents and
short-term investments totaled $26.2 million and $26.4 million, respectively.
The Company expects that its existing capital resources, interest earned
thereon, and product sales will enable the Company to maintain its current and
planned operations at least through mid-2000.
Historically, the Company has financed its operations primarily through the
private placement and public offering of its equity securities, research
contract licensing fees, and to a lesser extent, through federally sponsored
research grants. In June 1998, the Company raised additional funds through a
public offering of 1,725,000 shares of its Common Stock at a price of $12.00 per
share, including the exercise of the over-allotment option of 225,000 shares.
The Company also has established a $1.5 million line of credit with a bank. As
of March 31, 1999, the Company had no borrowings against the line of credit.
7
<PAGE> 10
The Company may need to raise additional capital to fund its future operations.
The Company's future capital requirements will depend on, and could increase as
a result of many factors, including, but not limited to: the commercial success
of its ADCON(R) family of products, the progress of the Company's research and
development, including the costs related to its Cognition Modulation and AD
programs, the scope, timing and results of preclinical studies and clinical
trials, the cost and timing of obtaining regulatory approvals, its success in
obtaining the strategic alliances required to fund certain of its programs, the
rate of technological advances, determinations as to the commercial potential of
certain of the Company's product candidates, the status of competitive products
and the establishment of additional manufacturing capacity.
In September 1998, the Company was awarded its second Phase II Small Business
Innovation Research ("SBIR") program grant from National Institute of
Neurological Disorders and Stroke ("NINDS") for research evaluating H(3)
agonists. The grant has a two-year term and may provide as much as $750,000 in
funding. In the second quarter of 1998, the Company was awarded two Phase I
SBIR grants for up to $97,500 each from National Heart, Lung and Blood Institute
and National Institute of Mental Health, both divisions of the National
Institute of Health ("the NIH"). The Company was also awarded a Phase I SBIR
grant for up to $99,800 in the third quarter of 1998 to aid in additional
research studies. If the Company is successful in other Phase I research,
additional Phase II awards may be sought for funding to aid in further
development of pharmaceutical compounds, however there is no assurance that such
Phase I research will be successful or that additional funding will be obtained.
The Company may raise additional funds through additional equity or debt
financing, government grants, future corporate alliances, collaboration
relationships or otherwise. The Company may engage in these capital raising
activities even if it does not have an immediate need for additional capital at
that time. There can be no assurance that any such additional funding will be
available to the Company or, if available, that it will be on acceptable terms.
If additional funds are raised by issuing equity securities, further dilution to
existing stockholders may result. If adequate funds are not available, the
Company may be required to delay, or reduce the scope of, or eliminate one or
more of its research, development or clinical trials. If the Company seeks to
obtain funds through arrangements with collaborative partners or others, such
partners may require the Company to relinquish rights to certain of its
technologies, product candidates or products that the Company would otherwise
seek to develop or commercialize itself.
YEAR 2000. The Year 2000 issue results from computer programs and systems that
were created to accept only two digit dates. Such systems may not be able to
distinguish 20th century dates from 21st century dates. This could result in
miscalculations and system failures that could inhibit the Company's ability to
engage in normal business activities.
The following discussion of the implications of the Year 2000 issue for the
Company contains numerous forward-looking statements. The cost of the Company's
Year 2000 project and the date upon which the Company plans to complete its
internal modifications are based upon management's best estimates, which were
derived utilizing a number of assumptions of future events including the
8
<PAGE> 11
continued availability of internal and external resources, third party
modifications and other factors. Although management believes it will be able to
make the necessary modifications in advance, there can be no guarantee that
these estimates and timetable will be achieved and actual results could differ
materially from those anticipated.
In addition, the Company relies upon the computer systems of certain third
parties such as customers, suppliers and financial institutions. Although the
Company is assessing the readiness of these third parties and preparing
contingency plans, there can be no guarantee that the failure of these third
parties to modify their systems in advance of December 31, 1999 would not have a
material adverse effect on the Company.
State of Readiness. In 1998, the Company commenced a program intended to
mitigate and prevent the adverse effect of the Year 2000 issue. This program
consists of the following phases:
AWARENESS PHASE-development of a detailed strategic approach to address
the Year 2000 issues;
ASSESSMENT PHASE-an assessment of all computer systems, software,
building infrastructure components and equipment with embedded
technology to identify each item that will require date code
remediation and an assessment and certification of third parties' Year
2000 compliance;
REMEDIATION PHASE-implementation of code enhancements, hardware and
software upgrades, systems replacements, vendor and customer
assurances, contingency planning and other associated changes; and
VALIDATION PHASE-testing of systems for Year 2000 readiness. The
Company believes that its network information systems, including
Network Operating Systems (NOS) software and Enterprise Resource
Planning (ERP) software have been thoroughly tested as Year 2000
compliant, and should be able to process year and data information
beyond the year 1999.
RISKS. The Year 2000 issue presents a number of risks and uncertainties
that could affect the Company, including failure of utilities,
competition for skilled personnel and disruption of Company operations
due to system failures or operational failures of third parties. With
respect to risks associated with the Company's computer systems and
equipment, management believes that it will be able to make the
necessary modifications and conversions in advance of the Year 2000.
With respect to risks associated with the failure of computer systems
or equipment of third parties, the Company could experience a material
adverse impact on its operations if such third parties fail to make
timely conversions or modifications. The most serious impact on the
Company operations in this regard would result if basic services such
as telecommunications, electric power, financial services and other
non-IT processes were disrupted.
9
<PAGE> 12
The Awareness Phase has been completed. The Company expects the Assessment and
Remediation Phases to be substantially completed by the end of the second
quarter of 1999. The Company's Remediation Phase consists of numerous individual
projects that vary in size, materiality and importance. The Company has
established a Year 2000 project team that is currently reviewing information
technology ("IT") systems and non-IT systems that could be affected by this
issue. While the manufacture of the Company's products are not dependent on
computer chip driven processes, any interruption in receipt of supplies,
delivery of goods by outside carriers, or processing of orders by distributors
could have a material adverse effect on the Company's business, prospects,
financial condition or result of operations. The Company has begun communicating
its Year 2000 status to all of its existing customers and vendors. In this
communication, the Company has requested that these same customers and vendors
respond with their Year 2000 status. The Company is maintaining a database of
customers and vendors who have and have not responded to such inquiry, and the
Company will promptly submit further inquiries to certain of such third parties
as business requirements dictate. However, there can be no guarantee that these
measures will prevent any material adverse effect on the operations and business
of the Company if such suppliers and business partners fail to convert their
systems before December 31, 1999.
COSTS. The Company is primarily utilizing internal resources to reprogram,
replace and test its computer systems, software, equipment and building
infrastructure components for Year 2000 modifications. The Company estimates
that Year 2000 expenditures will be less than $150,000 and will be funded by
normal operating cash flow. All Year 2000 expenditures are expensed as incurred
and are not expected to have a material effect on results of operations,
liquidity or capital resources. As of March 31, 1999 approximately $10,000 of
the estimated project cost has been incurred. The remaining costs are expected
to be incurred evenly over the period up through January 31, 2000. These cost
estimates may change as additional remediation and testing efforts progress.
CONTINGENCY PLANS. The Company is in the process of developing business
resumption contingency plans specific to the Year 2000. These plans will address
the actions that would be taken if critical business functions cannot be carried
out in the normal manner upon entering the next century due to systems or third
party failures. Management estimates that these contingency plans will be
developed by the end of the second quarter of 1999.
EURO CONVERSION. On January 1, 1999, eleven of the fifteen countries (the
"Participating Countries") that are members of the European Union established a
new uniform currency know as the "Euro." The current currency existing prior to
such date in the Participating Countries will be phased out during the
transition period commencing January 1, 1999 and ending January 1, 2002. During
such transition period both the Euro and the existing currency will be available
in the Participating Countries. Although certain of the Company's products are
being sold in the Participating Countries through independent distributors, the
Company receives revenues from such sales in U.S. dollars. As a result, the
Company does not anticipate that the introduction and use of the Euro will
materially affect the Company's business, prospects, and results of operations
or financial condition.
10
<PAGE> 13
FORWARD-LOOKING STATEMENTS. Certain statements in this Quarterly Report on Form
10-Q constitute "forward-looking statements." When used in this Report, the
words "believes," "anticipates," "expects," "intends" and other predictive,
interpretive and similar expressions are intended to identify such
forward-looking statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual results
of the Company to be different from expectations expressed or implied by such
forward-looking statements. Such factors included, but are not limited to,
commercial uncertainty of market acceptance of the Company's ADCON(R) family of
products, other than ADCON(R)-L, including the timing and content of decisions
made by the FDA, commercial uncertainty of the acceptance of the Company's
ADCON(R) family of products, delays in product development of additional
ADCON(R) products, uncertainty due to the early stage of development for the
therapeutic programs, the possible need for additional funding, the ability of
the Company to establish and maintain collaborative arrangements with others,
the potential market size of ADCON(R) products, the ability to extend research
collaborations, the ability of the Company, its customer and vendor to
appropriately address Year 2000 issues, the productivity of distributors of the
ADCON(R) products, shortages of supply of ADCON(R) products from the Company's
sole manufacturer, the ability of the Company to commence manufacturing of its
ADCON(R) products at its manufacturing facility located in the U.S., the lack of
supply of raw materials for the Company's products, uncertainty of future
profitability, uncertainties related to the Company's proprietary rights in its
products, the loss of key management, and personnel and technological change.
These statements are based on certain assumptions and analysis made by the
Company in light of its experience and its perception of historical trends,
current conditions, expected future developments and other factors it believes
are appropriate in the circumstances. Such statements are subject to a number of
other assumptions, risks, uncertainties, general economic and business
conditions, and the business opportunities (or lack thereof) that may be
presented to and pursued by the Company. Prospective investors are cautioned
that any such statements are not guarantees of future performance and that
actual results or developments may differ materially from those projected in the
forward-looking statements.
11
<PAGE> 14
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK
The Company does not enter into derivative financial instruments. The Company
primarily invests in commercial paper and corporate bonds that have short-term
maturities. The Company has no outstanding debt. Exposure to foreign currency
has been minimal because the Company's foreign product sales are in U.S.
currency. As a result, the Company believes that its market risk exposure is not
material to the Company's financial position, liquidity or results of
operations.
12
<PAGE> 15
PART II
OTHER INFORMATION
ITEM 2: CHANGES IN SECURITIES AND USE OF PROCEEDS
(a) RECENT SALES OF UNREGISTERED SECURITIES
On January 8, 1999, the Company issued an aggregate of 5,198 shares of common
stock, par value $.01 per share, to certain of its executive officers as part of
such officers bonus compensation for performance in fiscal 1998. These shares
were issued in a transaction exempt from registration pursuant to Section 4(2)
of the Securities Act of 1933.
(b) CHANGES IN SECURITIES AND USE OF PROCEEDS
The Company registered 2,300,000 shares of Common Stock in connection with its
initial public offering on a Registration Statement on Form S-1, which went
effective on October 18, 1995. The data below reflects the use of proceeds from
such offering to the date of this Quarterly Report on Form 10-Q. All such
proceeds were directly or indirectly paid to others pursuant to Rule
701(f)(4)(vii):
<TABLE>
<S> <C>
Construction 0
Machinery and Equipment 0
Real Estate 0
Acquisition 0
Repayment of Debt 0
Working Capital 711,000
Temporary Investments (specify)
Commercial paper 171,000
Corporate Bonds 271,000
Other Short-Term Investments 304,000
Other:
Clinical Trials 4,140,000
Research and Development 10,694,000
Sales and Marketing 3,283,000
General Corporate Purposes 73,000
</TABLE>
13
<PAGE> 16
ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
27.1 Financial data schedule
(b) Reports on Form 8-K
The Company did not file any Current Reports on Form 8-K for the period
covered by this Quarterly Report on Form 10-Q
14
<PAGE> 17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: May 14, 1999 GLIATECH INC.
By: /s/ Rodney E. Dausch
----------------------------------
Rodney E. Dausch
Vice President, Chief Financial Officer
and Secretary
(Duly Authorized Officer and Principal
Financial and Accounting Officer)
15
<PAGE> 18
EXHIBIT INDEX
Exhibit No. Description of Exhibit Page Number
- ----------- ---------------------- -----------
27.1 Financial Data Schedule 17
16
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GLIATECH
INC.'S QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 3,554
<SECURITIES> 22,641
<RECEIVABLES> 4,053
<ALLOWANCES> 549
<INVENTORY> 1,298
<CURRENT-ASSETS> 31,879
<PP&E> 4,028
<DEPRECIATION> 1,961
<TOTAL-ASSETS> 34,649
<CURRENT-LIABILITIES> 6,593
<BONDS> 0
0
0
<COMMON> 95
<OTHER-SE> 27,961
<TOTAL-LIABILITY-AND-EQUITY> 34,649
<SALES> 7,756
<TOTAL-REVENUES> 8,285
<CGS> 1,147
<TOTAL-COSTS> 1,147
<OTHER-EXPENSES> 6,917
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 474
<INCOME-TAX> 0
<INCOME-CONTINUING> 474
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 474
<EPS-PRIMARY> .05
<EPS-DILUTED> .05
</TABLE>
